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Chronic obstructive pulmonary disease (COPD) affects 6% of the general population and is
the fourth-leading cause of death in the United States with severe and very severe disease
accounting for 15% and 3% of physician diagnoses of COPD. Guidelines make few
recommendations regarding providing the provision of care for the most severe stages of
disease, namely Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages III and
IV with chronic respiratory failure.
The effectiveness of inhaled drug therapy in very severe patients has not been assessed yet.
Health care systems in many countries include public funding of long-term oxygen therapy for
eligible candidates. Currently, there is little evidence for the use of mechanical ventilatory
support in the routine management of hypercapnic patients. Pulmonary rehabilitation should
be considered as a signiﬁcant component of therapy, even in the most severe patients.
Although Lung Volume Reduction Surgery has been shown to improve mortality, exercise
capacity, and quality of life in selected patients, this modality is associated with signiﬁcant
morbidity and an early mortality rate in the most severe patients. Despite signiﬁcant progress
over the past 25 years, both short- and long-term outcomes remain signiﬁcantly inferior for
lung transplantation relative to other ‘‘solid’’ organ recipients.
Nutritional assessment and management is an important therapeutic option in patients
with chronic respiratory diseases. Morphine may signiﬁcantly reduce dyspnoea and does
not signiﬁcantly accelerate death. No consistent improvement in dyspnoea over placebo
has been shown with anxiolytics. Supplemental oxygen during exercise reduces exertional
breathlessness and improves exercise tolerance of the hypoxaemic patient. Non-invasive
ventilation has been used as a palliative treatment to reduce dyspnoea.
Hypoxaemic COPD patients, on long-term oxygen therapy, may show reduced health-
related quality of life, cognitive function, and depression. Only a small proportion of
patients with severe COPD discuss end-of-life issues with their physicians.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Improving the quality of care for patients at the end of life
has become a major goal of the medical community and the
general public.1 Current chronic obstructive pulmonary
disease (COPD) guidelines make few recommendations on
the care for the most severe patients i.e. those with Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
stages III and IV with chronic respiratory failure.2,3 Until
recently, little attention was paid to the health care needs
of the most severe COPD patients, despite the fact that as
many patients with COPD die each year as those with lung
cancer, and health decline occurs over a substantial period
before that.4
Size of the problem: COPD affects 6% of the general
population and is a leading cause of morbidity and mortality
worldwide. Age-adjusted mortality continues to increase at
difference with mortality from other leading causes of
death, including cardiovascular disease and cancer.2,5 In a
Dutch study severe and very severe disease assessed by post-
bronchodilator FEV1 accounted for 15% and 3% of physician
diagnoses of COPD.6 The 0.13% of the population in
O’ Stersund, Sweden in 2004 had physician-diagnosed stage
IV COPD.7 In an Italian study of prevalence rate, GOLD stages
III and IV were 4.5% and 0.4%, respectively, in males and
2.2% and 0.3% in females.8 Similar prevalence is reported in
ﬁve cities of South America.9
Mortality: GOLD stage III or IV patients are more likely to
comprise the most rapidly declining lung function quartile
with a modestly increased risk of death and time to a COPD-
related hospitalisation.10 Mannino et al.11 classiﬁed subjects
using a modiﬁcation of the GOLD criteria for COPD
(prebronchodilator FEV1) stratiﬁcation of disease severity,
and added a ‘‘restricted’’ category (FEV1/FVC470% and
FVCo80% predicted). They used Cox proportional hazard
models to determine the risk of impaired lung function on
subsequent mortality, after adjusting for age, race, sex and
smoking status. The overall rate of death was 8.9 per 1000
person years, but varied from 5.4/1000 among normal
subjects to 42.9/1000 among subjects with GOLD Stage III or
IV COPD. After adjusting for covariates, all GOLD categories,
along with the restricted category, predicted a higher risk ofdeath: GOLD Stage III or IV, hazard ratio (HR) 5.7, 95% GOLD
Stage II HR 2.4, 95%; GOLD Stage I HR 1.4, 95%; GOLD Stage 0
HR 1.5, 95%; and restricted HR 2.3, 95% CI 1.9, 2.8.
Increased mortality has been observed in patients with
older age, lower body mass index (BMI), need of oxygen
utilisation and greater hyperinﬂation. Exercise capacity, as
quantiﬁed by cardiopulmonary exercise testing, proves a
powerful independent predictor of survival.12 Even when
properly adjusted for potential confounding factors, women
with severe COPD on Long-Term Oxygen Therapy (LTOT)
have a greater risk of death than men.13
Exacerbations. Almost one-fourth of the COPD patients
had died within a year of ﬁrst hospital admission for the
disease. This group with a poor prognosis made abundant
use of hospital services. The burden imposed on such
services by severe COPD patients is U-shaped, with hospital
use increasing towards the end of their lives.14
Patients admitted to Intensive Care Unit (ICU) with
an acute exacerbation of COPD have a median survival
of 2 years, and 50% of patients are readmitted to the
hospital within 6 months.15 Prediction of survival status
may be enhanced by considering arterial oxygen tension,
albumin, BMI, disease duration and time elapsed since
the ﬁrst hospitalisation.16 In these patients hypercapnia at
discharge is related to inspiratory work, respiratory
muscle strength, and breathing pattern.17 The mortality
rate after an acute exacerbation is high, especially for older
patients with chronic respiratory failure in whom the
symptom burden in the last 6 months of life is signiﬁ-
cant.18,19 The 6-year mortality of patients with COPD
requiring ICU admission is substantial and is mainly
inﬂuenced by pre-ICU admission quality of life (QOL). At
6 years, around 15% are alive; survivors have a worse QOL
compared with pre-ICU admission, although three quarters
are self-sufﬁcient.20
Systemic effects: COPD affects many organ systems in
addition to the lungs.21 The risk of atherosclerosis,
cardiovascular disease and mortality is further increased in
COPD individuals who smoke.22,23 Chaouat et al.24 reported
severe pulmonary hypertension in less than 5% of patients.
Such patients had severe exertional dyspnoea, a short life
expectancy, hypocapnia, very low DLCO, and haemodynamic
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hypertension.
There is emerging evidence that poor exercise capacity
and peripheral muscle dysfunction may be linked by the
presence of systemic inﬂammation. Patients with COPD have
higher levels of C-reactive protein independent of coexisting
cardiac or non-cardiac risks.25,26 Those patients also show
increased levels of peripheral muscle apoptosis27 and local
oxidative stress.28 Patients with severe COPD become less
mobile and reduce their activities of daily living (ADL). In a
survey of patients with severe COPD (Medical Research
Council dyspnoea grade 5) treated with LTOT, 50% did not
leave the house and 78% were breathless walking around at
home and performing ADL.29 In one study,30 patients with
severe COPD with at least one hospital admission for
hypercapnic respiratory failure were compared to patients
who had been treated for unresectable non-small cell lung
cancer (NSCLC). This study showed that COPD patients had
signiﬁcantly less ability to perform the ADL, and lower social
and emotional functioning than patients with NSCLC.30
These patients are more likely to die with aggressive,
technological care to prolong life and are less likely to
receive home nursing and palliative care services than
patients with lung cancer, despite having similar prefer-
ences for palliation.15,31Treatment perspectives for survival
Drug therapy: Only smoking cessation32 and LTOT33,34
improve survival in COPD.2,3 Studies have shown an
association between inhaled corticosteroids and a reduction
in mortality and re-hospitalisation35,36 and a recent meta-
analysis of long-term trials with inhaled steroids reported a
signiﬁcant effect in reducing mortality from all causes in
patients with COPD.37 A large, randomised, controlled
clinical trial has tested this hypothesis prospectively38 and
results seem to show an advantage in survival by using
inhaled combination of long acting agonists with steroids.
Nevertheless the real effectiveness of inhaled drug therapy
in very severe patients has not been assessed yet.
Furthermore oral corticosteroids as maintenance treatment
in patients with end-stage respiratory disease are an
independent risk factor for death, and should be avoided
in most cases.39
Oxygen: It has been clearly established that selected
patients with COPD with chronic hypoxaemia live longer
when they receive LTOT,33,34 an effect maybe also due to
prevention of exercise induced oxidative stress.40 As a
result, health care systems in many countries include public
funding of LTOT for eligible applicants. However, as some
patients may no longer meet eligibility criteria at some time
after the initial prescription, uncertainty remains as to the
modalities of re-evaluation of these patients to maintain or
withdraw this long-term treatment.41 Reassessment of
applicants for LTOT after a long period of stability will
identify a signiﬁcant proportion of patients who are no
longer eligible, thus reducing costs and use of resources
without affecting QOL or mortality in these patients.42
Long-term domiciliary non-invasive mechanical ventila-
tion: Mechanical ventilation increases or substitutes for
spontaneous respiration, as in the case of acute respiratoryor ventilatory pump failure. Non-invasive positive pressure
ventilation (nPPV), delivered by nasal mask, has recently re-
emerged as an option that avoids the risks associated with
invasive ventilation. nPPV is thought to assist ventilation, by
improving inspiratory ﬂow rate and correcting hypoventila-
tion. Other possible mechanisms of action include unloading
respiratory muscles and resetting the central respiratory
drive.43 In contrast to the evidence supporting the use of
nPPV for other causes of chronic respiratory failure, there is
conﬂicting evidence regarding the beneﬁts of nPPV in COPD.
One trial published as an abstract indicates that there is no
overall survival beneﬁt in patients receiving nPPV plus LTOT,
although there may be a slight improvement in survival for
patients over 65.44 A 2-year multi-centre study also
examined the effects of nPPV plus LTOT compared with
LTOT alone. In this trial, nPPV plus LTOT improved PaCO2
during breathing of the usual oxygen inspiratory fraction.
Long-term improvements were also noted in dyspnoea and
QOL in the nPPV plus LTOT group, but survival was similar
between treatment groups.45 Home nocturnal nPPV added to
daytime exercise training has been found to signiﬁcantly
increase exercise capacity and QOL compared with exercise
training alone.46 Taken together all studies indicate that
currently, there is little evidence for the use of mechanical
ventilatory support in the routine management of hyper-
capnic COPD patients. However, further large studies may
be able to identify subsets of patients able to take
advantage from this therapy.43
Rehabilitation: COPD patients who perform regular
exercise activity have reduced risk of both hospital admis-
sion and mortality.47 Exercise training as part of pulmonary
rehabilitation appears to counteract increased exercise-
associated oxidative stress.48 Several studies provide scien-
tiﬁc evidence that rehabilitation improves several of the
variables associated with poor outcomes, such as exercise
capacity and dyspnoea,49 as well as the multidimensional
BODE index.50,51 In the study51 the changes in the BODE
index induced by rehabilitation were predictive of ﬁnal
outcome. Recently studies have reported the beneﬁcial
effects of physiotherapy in COPD patients also in the ICU
setting.52,53 Patients receiving chronic ventilation are weak
and deconditioned but respond to aggressive whole-body
and respiratory muscle training with an improvement in
strength, weaning outcome, and functional status.54
Pulmonary rehabilitation should be considered a signiﬁ-
cant component of therapy, even in most severe patients.49
Nevertheless in these severe COPD patients extreme
breathlessness and/or peripheral muscle fatigue may pre-
vent patients from higher levels of exercise intensity.
Increased inspiratory muscle work may contribute to
dyspnoea and exercise limitation. Several studies have
shown that continuous positive airway pressure (CPAP) and
different modalities of ventilatory assistance delivered
through nasal or facial mask during exercise, may reduce
dyspnoea and work of breathing and enhance exercise
tolerance in COPD patients. Inspiratory support provides
symptomatic beneﬁt by unloading and assisting such over-
burdened ventilatory muscles, whereas CPAP counterba-
lances the intrinsic positive end-expiratory pressure
(PEEPi).55,56 Nevertheless, the role of assisted ventilation
in pulmonary rehabilitation is still controversial: additional
beneﬁt of assisted ventilation on exercise tolerance,
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strated when compared with training alone. Larger pro-
spective controlled studies should be undertaken to
determine if assisted ventilation may eventually have
routine applicability, and in particular subgroups of
patients.57
Neuromuscular electrical low-voltage stimulation has
been shown to induce an increase in the muscular oxidative
capacities. Small controlled studies of this technique in
severe COPD patients have been reported.55
Lung volume reduction surgery: Lung volume reduction
surgery (LVRS) is used to treat patients with severe
emphysema by removing the most damaged areas of the
lung, thus reducing hyperinﬂation. Although LVRS has been
shown to improve mortality, exercise capacity, and QOL in
selected patients with upper lobe disease and poor exercise
capacity compared with patients randomised to medical
therapy, this modality is associated with signiﬁcant morbid-
ity and an early mortality rate of about 5% in the most
severe patients.59,60 For these reasons, and because of the
high risk of the procedure for patients with the most severe
disease, alternatives have been studied, including broncho-
scopic lung volume reduction and endobronchial valve
placement. These techniques have been shown to improve
mean exercise capacity and reduce dynamic hyperinﬂation
in a subgroup of patients with COPD.61
Lung transplantation: Lung transplantation is an option
for a more limited number of patients. A COPD patient can
be considered an appropriate candidate for transplantation
when the FEV1 is below 25% predicted and/or the PaCO2 isX
¼ 55mmHg. Despite signiﬁcant progress over the past 25
years, both short- and long-term outcomes remain signiﬁ-
cantly inferior for lung recipients relative to other ‘‘solid’’
organs.62 Pulmonary function generally improves after lung
transplantation, but exercise capacity remains below pre-
dicted values, primarily due to a peripheral muscle
myopathy.62 Pulmonary rehabilitation programs can improve
the exercise tolerance and QOL in both short and long term
after lung transplantation.63 Long-term results of lung
transplantation are limited by signiﬁcant complications that
impair survival; an approximately 80% 1-year, 50% 5-year,
and 35% 10-year survival has been reported. Bronchiolitis
obliterans is the most important long-term complication of
lung transplantation resulting in decreased pulmonary
function.64Nutrition
Survival studies have consistently shown signiﬁcantly great-
er mortality rates in underweight and normal-weight than in
overweight and obese COPD patients.65–67 Malnutrition is a
common and underrecognised problem in hospitalised
patients. Indeed hospitalisation is frequently associated
with negative energy balance and further deterioration in
nutritional status. A survey of admissions to a general
hospital reported a prevalence of malnutrition of 27–46%
across various hospital specialties.68,69 In particular nutri-
tional depletion is a common problem in COPD patients. It is
caused, to a large extent, by an imbalance between low-
energy intake and high-energy requirements,70 leading to
muscle wasting and dysfunction.71 A compromised nutritionis associated with a poor prognosis in stable COPD patients
with and without respiratory failure.72,73
In a study by Sivasothy et al.74 chronically ventilated
hypercapnic COPD patients with BMI value lower than 20
showed a worse survival. Other studies have conﬁrmed that
besides established prognosis factors such as FEV1 and PaO2,
nutritional depletion as assessed by BMI and overall systemic
inﬂammation as estimated by C-reactive protein appear as
major determinants of hospitalisation and death risks
whatever the end-stage respiratory disease. BMI and C-
reactive protein should be included in the monitoring of
chronic respiratory failure. Additionally, nutritional status
has been recently studied in 744 patients with different
underlying diseases on long-term respiratory treatments
(oxygen and/or mechanical ventilation).75 Authors have
found that fat-free mass (FFM), BMI below 20 and low serum
albumin were the most sensitive parameters detecting
malnutrition. In these conditions BMI has been reported
lower than 25, being more compromised in COPD than in
other thoracic diseases.76 Patients with COPD are at risk of a
low FFM and a low FFM is prevalent even among subjects
with normal BMI. Because FFM index is associated with
prognosis, it seems that assessment of FFM provides
important information in COPD and should be considered
in the routine evaluation of patients with this condition.77
Indeed in COPD patients semi-starvation and muscle atrophy
are equally distributed among disease stages, but the
highest prevalence of cachexia is reported in GOLD stage
IV. In a follow-up study, 46% of the patient died during a
maximum follow-up of 5 years. Cox regression models, with
and without adjustment for disease severity, showed that
FFM index was an independent predictor of survival. This
supports the inclusion of body-composition assessment as a
systemic marker of disease severity in COPD staging.78
Nutritional depletion is an independent risk factor for
mortality and hospitalisation in patients with COPD receiv-
ing LTOT. The best prognosis was observed in overweight and
obese patients.65,79 Clinical research has conﬁrmed the
negative impact of muscle wasting on patients’ survival.
Gain in body weight, muscle mass and strength has been
associated with better exercise tolerance and survival,51,73
therefore, improving peripheral muscle function could be a
reasonable therapeutic target in patients with COPD.
Pharmacological approaches to this problem, for instance
anabolic steroids80 and growth hormone81 supplementation
has been disappointing so far.
Nutritional assessment and management is an important
therapeutic option in patients with chronic respiratory
diseases,82 especially those dealing with prolonged/difﬁcult
weaning from mechanical ventilation in ICU.83 Speciﬁc
nutritional deﬁciency like hypophosphatemia84 and impaired
lipid synthesis85 can also be associated with acute respira-
tory failure and with an abnormal increase in the fat mass of
these patients, respectively. These patients often complain
of dietary problems such as ‘anorexia’, ‘dyspeptic symptoms
other than diarrhoea’, ‘slimming’, ‘fear of gaining weight’,
‘dyspnoea’, ‘diarrhoea’, ‘depression, anxiety, solitude’. It
has been observed that smoking habits and gender have
impact on the kind of dietary problems reported. Reporting
two dietary problems correlated to low FFM index, whereas








Figure 1 Diagram of main goals of care according to disease
stage.
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needing prolonged mechanical ventilation is swallowing
dysfunction. Although this dysfunction is usually induced
by an underlying neuromuscular disease, many factors may
also contribute including: acute illness and medications used
to treat these conditions (steroids, neuromuscular blocking
agents, general sedatives), prolonged inactivity of swallow-
ing muscles, injury due to endotracheal intubation, tra-
cheostomy tube.76 Tracheostomy per se may limit
swallowing function by either compressing the oesophagus
or decreasing larynx elevation and anterior displacement
thus increasing the chances of aspiration.87 Recent studies
both in acute and chronic setting suggested that swallowing
dysfunction and pulmonary aspiration occur in patients
receiving ventilatory support through a cuffed tracheostomy
tube. Therefore, dietary intake through the mouth should
be carefully evaluated. Recognition of swallowing dysfunc-
tion in these patients may identify patients at high risk of
aspiration, and thereby help to avoid pulmonary related
complications such as pneumonia and atelectasis.88 In
tracheostomised difﬁcult-to-wean COPD patients under
unassisted breathing, meals may induce increase in respira-
tory rate, end-tidal CO2 and dyspnoea, in this condition
inspiratory pressure support ventilation prevents dyspnoea
from worsening during meals.89
Enteral nutrition by means of oral nutritional supplements
(ONS) or tube feeding (TF) enables nutritional intake to be
maintained or increased when normal intake is inadequate.
In COPD patients, enteral nutrition in combination with
exercise and anabolic pharmacotherapy has the potential to
improve nutritional status and function. Frequent small
amounts of ONS are preferred in order to avoid postprandial
dyspnoea and satiety as well as to improve compliance.90
However, a meta-analysis has provided no evidence that
nutritional support has a signiﬁcant effect on anthropo-
metric measures, lung function, or exercise capacity in
patients with stable COPD.91,92 By contrast, repeated
administration of ghrelin, a novel growth hormone-releasing
peptide that is reduced in COPD93 may improve body
composition, muscle wasting, and functional capacity in
cachectic patients with COPD, thus possibly reversing some
of the systemic aspects of COPD.94
Supportive therapy
As in other chronic diseases when severity of disease
increases along the natural history, therapy aimed to
prolong life become less and less important in comparison
to palliative therapy aimed to relieve symptoms (Fig. 1).
Drug therapy of dyspnoea
The symptomatic treatment of dyspnoea remains relatively
ineffective and is often accompanied by signiﬁcant adverse
effects.95 In patients with advanced emphysema, dyspnoea
is an incapacitating symptom that commonly indicates the
onset of the ﬁnal stage of this illness. The most effective
treatments for dyspnoea in COPD are bronchodilators96 and
LVRS58 to improve the mechanical impairment, and pulmon-
ary rehabilitation49 to reduce ventilatory demand. These are
useful at all stages of the illness, but in end-stage disease arange of other less well validated approaches have been
tried.97
One possibility is to reduce ventilatory demand by
decreasing the central drive by opiates.98,99 Opiates have
been shown to decrease minute ventilation at rest and
during submaximal exercise. They can alter the central
processing of neural signals within the Central Nervous
System to reduce sensations associated with breathing. Also
the drug’s cardiovascular effects are thought to be
responsible for relieving dyspnoea. Therapeutic doses of
opioids induce peripheral vasodilation, reduce peripheral
vascular resistances and inhibit baroreceptors response.
Furthermore opioids reduce the anxiety associated with
dyspnoea. There is also speculation that they may act
directly on opioid receptors in the airways.100 Despite safety
concerns, these drugs do have place in the management of
patients in the terminal phase of their disease.101 Recent
meta-analysis102 has shown that morphine may signiﬁcantly
reduce dyspnoea, in patients with cancer, and does not
signiﬁcantly accelerate death in patients in whom mechan-
ical ventilation was withdrawn. Epidural methadone perfu-
sion at thoracic level can effectively palliate dyspnoea and
improve exercise capacity and QOL in patients with
advanced emphysema, without deterioration in respiratory
control or lung function.103 No consistent improvement in
dyspnoea over placebo has been shown with anxioli-
tics.104–106 Nonetheless the American Thoracic Society
(ATS) statement ‘‘recommend(s) a trial of anxiolitic therapy
on an individual basis’’.95
Decreasing central drive, that is reducing ventilatory
demand, obtained by altering pulmonary afferent informa-
tion to central controller potentially may reduce dyspnoea.
However, there are many concerns about the real usefulness
of such interventions in a clinical setting.107 The following
must be considered: (i) there is speculation that opioids may
act directly on opioid receptors in the airways100,108; (ii)
aerosolised topical anaesthesia has inconsistent effects on
dyspnoea109; (iii) vagal blockade has highly variable effects
on dyspnoea110; (iv) intact ventilatory response to exercise
in post-transplantated vagally denervated subjects has been
reported.111 Inhalation of furosemide alleviated the sensa-
tion of dyspnoea induced by constant-load exercise testing
in patients with COPD.112
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Decreasing ventilatory demands and/or gas density have
been recently shown to improve exercise tolerance,
symptoms, and QOL.113 A way to reduce metabolic load is
oxygen supplementation. Hypoxia has no dyspnogenic effect
per se, it causes dyspnoea by stimulating minute ventilation.
Supplemental oxygen during exercise reduces exertional
breathlessness and improves exercise tolerance of the
hypoxaemic COPD patient by different mechanisms: reduc-
tion of hypoxic stimulation of the carotid bodies, pulmonary
vasodilation, increase in arterial oxygen. The latter two
mechanisms may potentially reduce carotid body stimula-
tion at heavy levels of exercise by increasing oxygen
delivery to the exercising muscles and reducing carotid
body stimulation by lactic acidaemia. Recent studies
indicate that also reduction in hyperinﬂation, that is
decrease in ventilatory impedance, plays an important role
in the oxygen-related relief of dyspnoea.113,114 Early
studies115 failed to demonstrate beneﬁts of supplemental
oxygen during rehabilitation. Nevertheless, a recent double
blind study of non-hypoxaemic patients with severe COPD
showed that patients trained with oxygen supplementation
increased training intensity and endurance more rapidly
than patients trained without.116
Manipulating gas density using heliox breathing has also
been shown to be beneﬁcial in relieving symptoms and
improving exercise capacity, for it facilitates gas emptying
during expiration. As a result, the amount of expiratory ﬂow
limitation and operational lung volumes decreases, thus
reducing ventilatory impedance and ultimately leading to
greater exercise tolerance.113,117–119
Non-invasive mechanical ventilation
Non-invasive ventilation has been used increasingly
as an alternative to invasive ventilation in patients with a
‘do not intubate’ order. In a recent study,120 nPPV was
applied to treat episodes of acute respiratory failure in 114
patients with ‘do not intubate’ orders. About half of the
patients survived and were discharged from the ICU. Similar
results have been recently obtained by Schettino et al.,121
and Chan et al.122 so that there is increasing recognition that
nPPV may be an effective alternative to intubation
especially in those patients in which an invasive approach
is questionable because of the presence of a chronic disease
or poor life expectancy. Interestingly, in 40% of the patients
undergoing nPPV this was used solely as a palliative
treatment, as it has been shown that nPPV may reduce
dyspnoea shortly after initiation not only during an episode
of hypercapnic respiratory failure123 but also in terminally
ill patients.124
Health status and psychological effects
Although the underlying pathology is initially conﬁned to the
lungs, the associated psychological responses to COPD
contribute greatly to the resulting morbidity. The ability to
function in ADL, as well as the QOL of a patient with COPD,
may be further complicated by psychological complaints or
even a concurrent mental disorder. Although the physicalillness itself probably contributes to the occurrence and
severity of the psychological complaints, this does not mean
that these complaints will be resolved once the respiratory
complaints are treated. Hypoxaemic COPD patients, in LTOT,
may show reduced QOL, decreased ability to cope with ADL,
cognitive function, and depression.125,126
As greater numbers of patients survive intensive care it is
becoming increasingly evident that QOL after critical illness
may be compromised. It has been found that nearly half of
patients who survive ARDS manifest neurocognitive sequelae
2 year after their illness. Anxiety and depression were also
common and QOL was poor.127 Information on health status
of patients after acute respiratory failure due to acute COPD
exacerbations requiring ICU admission are scanty. COPD
patients surviving acute on chronic respiratory failure and
requiring mechanical ventilation suffer worsened perceived
health status and cognitive function than stable COPD
patients on LTOT who have never previously required ICU/
RIICU admission. After discharge the health and cognitive
status may improve to levels similar to those of stable COPD
patients on LTOT.128
In daily practice, the presence of psychological
complaints or mental disorders in patients with COPD is
often regarded as a complication caused by the physical
complaints.129 As a result, they are regularly overlooked,
often remain undiagnosed and are rarely treated. COPD
patients experienced markedly more psychological
distress than a random sample from the general Dutch
population. The prevalence of depression in patients
with severe or very severe COPD was 37% compared with
22% in patients with mild or moderate COPD.130 Van Manen
et al. also found that patients with severe airways
obstruction were at an increased risk of depression in
comparison with mild to moderate COPD (25 versus 20%).131
Other results132 show that less than 40% of anxiety or
depressive disorders in COPD patients are recognised. It
appears that only 30% of patients with depression or anxiety
and only a slightly higher percentage of those with severe
anxiety and/or depression are being treated. These data
also suggest that despite treatment, many patients still
meet criteria for a depressive and/or anxiety spectrum
illness.
Few studies have examined the neuropsychological
complications associated with end-stage pulmonary
disease. Neuropsychological data were shown for 47 patients
with end-stage COPD, candidates for lung transplantation.
Patients exhibited a variety of neurocognitive deﬁcits.
Speciﬁcally, over 50% of the patients exhibited impaired
immediate free recall and consistent long-term retrieval
deﬁcits, while more than 44% of these individuals
displayed deﬁcient long-term retrieval. Deﬁcient long-
term storage strategies, cued recall, and delayed recall
were exhibited by between 26% and 35% of these patients,
while more than 32% of this sample displayed elevated
numbers of intrusion errors.133 Separate and distinct
personality styles that could affect QOL, the need for
adjunct treatments, and medical compliance emerged from
a sample of individuals with end-stage lung disease.134
Furthermore the results of a small randomised trial
indicated that patients with end-stage COPD may beneﬁt
from antidepressant drug therapy when signiﬁcant depres-
sive symptoms are present.135
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In recent times the simple principles of beneﬁcence and
non-maleﬁcence have been augmented and sometimes
challenged by a rising awareness of patient/consumer
rights, and the public expectation of greater involvement
in medical, social and scientiﬁc affairs which affect them. In
a publicly funded health care system in which rationing
(explicit or otherwise) is inevitable, the additional concepts
of utility and distributive justice can easily come into
conﬂict with the individual’s right to autonomy. Possible
treatment options for end-stage lung disease include
transplantation and long-term invasive ventilation which
are challenging in resource terms. Other interventions such
as pulmonary rehabilitation and palliative care are rela-
tively low cost but not uniformly accessible.136
Patients with COPD have a poor QOL and limited life
expectancy. A study examined whether these patients were
relatively disadvantaged in terms of medical and social care
compared with a group with inoperable lung cancer.30 An
open two group comparison was made of 50 patients with
severe COPD (forced expiratory volume in 1 s (FEV1)o0.75 l
and at least one admission for hypercapnic respiratory
failure) and 50 patients with unresectable NSCLC. A multi-
method design was used involving standardised QOL tools,
semi-structured interviews, and review of documentation.
The patients with COPD had signiﬁcantly worse ADL and
physical, social, and emotional functioning than the patients
with NSCLC. Ninety percent of patients with COPD suffered
clinically relevant anxiety or depression compared with 52%
of patients with NSCLC. Patients were generally satisﬁed
with the medical care received, but only 4% in each group
were formally assessed or treated for mental health
problems. With regard to social support, the main difference
between the groups was that, while 30% of patients with
NSCLC received help from specialist palliative care services,
none of the patients with COPD had access to a similar
system of specialist care. Finally, patients in both groups
reported a lack of information from professionals regarding
diagnosis, prognosis and social support, although patients’
information needs were disparate and often conﬂicting. This
study suggests that patients with end-stage COPD have
signiﬁcantly impaired QOL and emotional well being which
may not be as well met as those of patients with lung cancer,
nor do they receive holistic care appropriate to their needs.
A palliative care approach, as used routinely in cancer,
might be also valid for incurable chronic illnesses such as
COPD. However, a London study recently reported that
general practitioners, who provide most end-stage care for
COPD patients, do not routinely discuss prognosis with these
patients.137
Increased and equal participation of patients in decision-
making about their care facilitates patient autonomy as a
fundamental ethical principle, although most medical care
systems recognise there are limits to care and physicians
need not pursue futile therapy.4 Despite widespread public
acceptance of the central role of the patient, decision-
making is based on the expectation that there are reliable
prognostic indicators for most lung conditions, the choices
available to patients are real, and that individuals can
meaningfully take part in complex decision-making. All
these assumptions are questionable. There are severalmajor impediments to planning end-of-life care, especially
in COPD patients. Prognosis may be hard to predict as a
gradual decline punctuated by acute exacerbations is the
usual course, but it is difﬁcult to know which exacerbation
will be the last. Perhaps as a consequence, difﬁcult
discussions and decision-making may be deferred, and
patients may not realise their condition has reached a
terminal phase. This makes end-stage planning problema-
tical and may explain why relatively few patients complete
advance directives. Of the main carers of COPD patients
interviewed by Elkington et al.,138 40% were not aware the
deceased might die. The carers felt that approximately 63%
of the deceased realised deﬁnitely or probably they might
die—but that leaves a substantial number who were unclear
about their own prognosis. Clearly these individuals cannot
plan adequately for death if they do not know it is
imminent. Regarding the place of death, it is also important
to note that signiﬁcantly more carers of subjects who died at
home felt this was the right place to die as opposed to
informants of those who died in hospital. In England, for
example, a current Department of Health initiative is aiming
to improve end-of-life care by ensuring more patients die in
the site of their choice (usually home).4Determinants of end-of-life decision-making
The timing and content of discussion about mechanical
ventilation in end-stage lung disease has been examined by
McNeely and colleagues.139 In this Canadian study respira-
tory medicine specialists were likely to embark on discus-
sions when the patients dyspnoea was reported as severe
(84.2%), or when FEV1 was less than 30% predicted. In total
43% reported they discussed mechanical ventilation with
40% or less of their COPD patients before an exacerbation
necessitated ventilatory support. The majority felt decision-
making was collaborative, but over half often or always
modiﬁed presentation of information provided to patients
in order to inﬂuence their decision about mechanical
ventilation.
Treatment preferences on life sustaining interventions
have been assessed in a range of patients with limited life
expectancy due to cancer, congestive cardiac failure or
COPD.140 Individuals of average age approximately 73 years
were asked whether they would wish to receive a given
treatment if the outcome was certain, or if there were
differing likelihoods of an adverse outcome. Importantly
participants were able to balance the outcome against the
burden of treatment (e.g. length of hospital stay, invasive-
ness of procedure). For example, a low burden treatment
that returned the individual to previous functioning level
would be accepted by nearly all participants (98.7%), but
11.2% would not accept this option of the treatment had a
high burden. Conversely, if the likely outcome was survival
but with severe functional or cognitive impairment 74.4%
and 88.8% would not want to receive low and high burden
treatment, respectively. There was no difference between
choices between the diagnostic groups, although there was
a trend for COPD and cancer patients to reject high burden
therapy. This work demonstrates that patients can evaluate
the personal impact of varying outcomes, and that the
impact on functional and cognitive performance play a
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itself. This should help inform discussion with patients.
Clearly they also need to know the probable consequences
of non-intervention to make a valid decision.
It is clear that the understanding of information by
patients depends not only on content, but on how that
information is framed. For example, patients are more likely
to favour an intervention with a 90% survival rate rather
than a 10% mortality rate. Relative risk reduction is often
assimilated better than actual rate reductions. Risks should
be set into context against every day risks. It is also likely
that personal accounts and narratives can lead to increased
identiﬁcation of risk. Visual presentation e.g. in the form of
a diagram or pie chart work better than a barrage of
numbers or graphs.
Decision aids
Decision aids, if developed appropriately can be very
effective. They can increase knowledge, improve the
proportion of patients with a realistic perceptions of beneﬁt
and harm from an interventions, reduce decisional conﬂict,
decrease the number of patients who remain undecided or
passive about choices, and can improve agreement between
the patient’s reported values and the option that is chosen.
An example is the instrument developed to elicit patient
preferences for intubation and mechanical ventilation in
COPD by Dales et al.141 This scenario-based tool consists of
an audiotape and booklet describing intubation, mechanical
ventilation and possible outcomes. The authors found that
use of the aid allowed 20 advanced COPD patients (10 male,
10 female) to reach a decision. Decisional conﬂict was low
and these choices remained stable over a year of follow-up.
The agreement between patients and their physicians
regarding choices was 65%. Interestingly far more females
chose to forego mechanical ventilation than males. Clearly
one problem concerns the options presented. Since this tool
was devised there has been increasing use of nPPV in acute
exacerbations and this recent information needs to be
incorporated in any up-to-date decision tool. In the decision
aid described above Dales et al.141 found no agreement
between decisions made by patients and surrogate decision-
maker. In a further study in end-stage renal patients on
haemodialysis Pruchno et al.142 found that decisions made
by spouses (as proxy) about continued dialysis in hypothe-
tical scenarios were completely in line with the spouses own
preferences for their care rather than the patient’s
preferences.
Advance directives
Advance directives are widely encouraged in order to
increase patient autonomy by allowing control over care
by specifying treatment choices and indicating surrogate
decision makers. Only around 30% of US citizens make
advance statements and in some countries this rate is
signiﬁcantly lower.143 They can work well in conditions
where the disease trajectory is clearer than in COPD Such as
Amyotrophic lateral sclerosis (ALS). The American Academy
of Neurology have reported that around 90% of ALS patients
have advance directives and these are followed in 97%.However, advance directives work less well in other
circumstances, and this may be a particular problem in
ICU. Instructions may be too vague to be of use or too
medically speciﬁc to be applied in common situations. They
tend to focus on the right to refuse treatment with little
emphasis on the underlying goals or values of the patient.
Once completed they are often not reviewed even when
health declines. These directives are based on patient
autonomy but in some cultures decisions are family or
religious-based. There are concerns from some disability
groups that directives deal predominantly with treatment
refusal where some groups would like to emphasise their
continued wish for treatment. Regardless of these com-
ments advance directives can work well for COPD patients.Improving communication
Opportunities to raise this end-of-life matters occur during
pulmonary rehabilitation sessions, although in group meet-
ings general topics rather than speciﬁc management plans
are easier to address. For example, Heffner et al.144 carried
out a two-site prospective evaluation of advance directive
education during a pulmonary rehabilitation course to assess
the effects on completion of (i) Living Wills, (ii) durable
powers of attorney (i.e. identifying a proxy decision-maker),
(iii) patient–physician discussion about end-of-life issues,
(iv) decisions about life support and (v) patient impression
that their physician understood their end-of-life prefer-
ences. The group that received education on these topics
was subsequently signiﬁcantly more likely to discuss these
issues, complete advance directives, and felt more assured
their physicians understood their preferences. It has been
demonstrated that COPD patients in particular want further
information on their disease course and treatments from
their doctors, but may not necessarily raise these topics
without prompting.145 They may not even be aware their
condition is progressive. The way the topics are raised is also
crucial. Most individuals welcome discussion but this is
usefully directed to the symptom control approach through-
out the remainder of the patient’s life, rather than an
exclusive focus on their death. Striking a realistic and kindly
balance between maintaining hope and a pragmatic ex-
pectation of decline is part of the clinical judgement health
care workers should exercise, and adapt to the individual.
Knauft and colleagues146 have recently examined barriers
to end-of-life discussions between patient and the care
team. In a focus group analysis of oxygen dependent COPD
patients and their physician, they found that only 32% of
patients had taken part in such discussion with their
physician. Frequently cited barriers were ‘I’d rather con-
centrate on staying alive’ and ‘I’m not sure which doctor
will be taking care of me’. Physicians ranked the most
important barriers as ‘There was too little time during our
appointment to discuss everything we should’, or ‘I worry
that discussing end-of-life care will take away his/her
hope’, and ‘The patient is not ready to talk about the care
he/she wants if he/she is sick’. It is evident that this topic is
easier to defer on both sides. On the other hand, the authors
found a number of facilitators which made effective
communication more likely. These included the patient’s
experience of friends or family who had died, the fact they
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good at caring for their lung disease, and that he/she
viewed them as person, rather than focusing purely on their
lung condition.
Finally and encouragingly, there is evidence that physi-
cian skills in discussing end-of-life care can be improved.
The oncology world is ahead of respiratory medicine in these
training initiatives which include video feedback sessions,
but the area is gaining increasing attention. At the same
there is every reason to foster a wider debate to raise public
awareness on advance directives and treatment options, and
increase the provision of palliative and supportive care for
our COPD patients.
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